|
|
|
In this exclusive UroToday clinical conversation series, multidisciplinary experts in urology, medical oncology, radiation oncology, nuclear medicine, and translational science explore the evolving role of radiopharmaceutical therapy across the prostate cancer continuum. Through practical, peer-to-peer discussions, this series examines today’s treatment landscape, the biological and mechanistic distinctions between emerging approaches, real-world considerations for clinical decision-making, and where the next wave of innovation may take the field.
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
Current Landscape and Unmet Needs
|
Dustin Boothe, MD, and Praful Ravi, MB, BChir, MRCP, and Philip Kantoff, MD
Praful Ravi and Dustin Boothe discuss the clinical positioning of lutetium-177 PSMA in metastatic CRPC with Philip Kantoff, working through patient selection, sequencing, and progression after Pluvicto.
|
|
|
|
|
|
|
|
|
|
|
|
Mechanisms and Clinical Considerations
|
Ken Herrmann, MD, MBA, Neil Bander, MD, Phillip Koo, MD, and Philip Kantoff, MD
Phillip Koo moderates a panel with Ken Herrmann, Philip Kantoff, and Neil Bander on alpha-emitting radiopharmaceuticals in prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Patient Selection and Treatment Sequencing
|
Dustin Boothe, MD, Neal Shore, MD, FACS, Tanya Dorff, MD, and Phillip Koo, MD
Tanya Dorff, Neal Shore, and Dustin Boothe discuss patient selection and treatment sequencing for lutetium-177 PSMA across the pre- and post-chemotherapy mCRPC settings.
|
|
|
|
|
|
|
|
|
| Radiation Safety, Patient Selection, and Clinical Gaps
|
| Dustin Boothe, MD, Neal Shore, MD, FACS, Tanya Dorff, MD, and Phillip Koo, MD
|
| Michael Morris and Rana McKay discuss regulatory endpoints and emerging immunotherapy strategies in advanced prostate cancer with Philip Kantoff.
|
|
|
|
|
|
|
|
|
Endpoints, Immunotherapy, and Future Directions
|
Rana McKay, MD, Michael Morris, MD, and Philip Kantoff, MD
In the second part of the Radiopharmaceuticals in Prostate Cancer: Patient Selection and Treatment Sequencing discussion, Phillip Koo continues the conversation with Dustin Boothe, Neal Shore, and Tanya Dorff on practical and clinical considerations in radiopharmaceutical therapy for prostate cancer.
|
|
|
|
|
|
|
|
|
| Payloads, Carriers, Targets, and Combinations |
| Rana McKay, MD, Michael Morris, MD, and Philip Kantoff, MD |
| Michael Morris and Rana McKay discuss isotope and carrier selection, combination strategies, and emerging targets in radiopharmaceutical therapy with Philip Kantoff. |
|
|
|
|
|
 |
|
|
|
|
|
